When to Test for H. pylori
Test for H. pylori in patients with uninvestigated dyspepsia (without alarm symptoms), documented peptic ulcer disease, gastric MALT lymphoma, after gastric cancer resection, in first-degree relatives of gastric cancer patients, and in high-risk racial groups (particularly non-Hispanic Black and Asian populations) ideally before age 40 for cancer prevention.
Clinical Scenarios Requiring Testing
Primary Indications for Testing
- Uninvestigated dyspepsia in patients without alarm symptoms: Use a "test-and-treat" strategy with non-invasive testing rather than proceeding directly to endoscopy 1
- Documented peptic ulcer disease: All patients with active or past peptic ulcers require testing
- Gastric MALT lymphoma: H. pylori eradication is first-line therapy
- Post-gastric cancer resection: To prevent metachronous lesions
- First-degree relatives of gastric cancer patients: Family history significantly increases risk
- High-risk populations for gastric cancer prevention: Screen-and-treat is most effective when performed before age 40, with optimal benefit at age 30 (NNS of 563 for non-Hispanic Black males) 2
Alarm Symptoms That Warrant Endoscopy Instead
If any of these are present, proceed directly to endoscopy with biopsy-based testing rather than non-invasive testing:
- Age >60 years with new-onset dyspepsia
- Unintended weight loss
- Gastrointestinal bleeding or anemia
- Progressive dysphagia
- Persistent vomiting
- Family history of gastric cancer
Choosing the Right Test
For Initial Diagnosis (Non-Invasive)
Stop PPIs for 2 weeks before testing 1. PPIs cause 10-40% false-negative rates by decreasing bacterial load in the stomach. If stopping PPIs is not possible, use validated IgG serology instead.
Preferred non-invasive tests:
- Urea breath test (UBT): Gold standard for non-invasive testing
- Stool antigen test (SAT): Comparable accuracy to UBT
- Serology: Only use if PPIs cannot be stopped; antibodies remain positive for months after eradication, making it unsuitable for post-treatment testing 1
For Patients Undergoing Endoscopy
When endoscopy is performed for other clinical indications:
- Rapid urease test: Quick bedside result
- Histology: Can detect H. pylori even with low bacterial load
- Culture with susceptibility testing: Essential in regions with high clarithromycin resistance (>15%) and after treatment failures 1
Critical caveat: In regions with high clarithromycin resistance, culture and susceptibility testing should be performed before first-line treatment if standard triple therapy is being considered 1.
Post-Treatment Testing (Confirmation of Eradication)
Always confirm eradication after treatment 3. This is not optional—it should be explained to patients when prescribing initial therapy.
Timing of Post-Treatment Testing
Wait at least 4 weeks after completing treatment before testing 1, 4, 3. Testing earlier risks false-negative results from temporary bacterial suppression. The 4-week minimum applies to:
- Urea breath test
- Stool antigen test
- Biopsy-based tests (if endoscopy performed)
Evidence on earlier testing: While one study showed the stool antigen test at 7 days post-treatment had 100% positive predictive value for treatment failure 4, and another showed UBT at 2 weeks was comparable to 4-6 weeks 5, the consensus guideline recommendation remains 4 weeks minimum to avoid false-negatives.
Preferred Post-Treatment Tests
- Urea breath test: Most accurate for confirming eradication
- Stool antigen test: Acceptable alternative, though may have slightly lower diagnostic value post-treatment 3
- Biopsy-based tests: If endoscopy is clinically indicated
- Serology: NOT recommended post-treatment (antibodies persist 6-12 months after eradication) 3, 6
Common Pitfalls to Avoid
Testing patients on PPIs: This is the most common error—10-40% false-negative rate. Either stop PPIs for 2 weeks or use serology 1
Using serology to confirm eradication: Antibodies remain elevated for months after successful treatment, making serology useless for post-treatment confirmation 3, 6
Testing too soon after treatment: Wait the full 4 weeks to avoid false-negatives from temporary suppression 4, 3
Not confirming eradication: Treatment failure occurs in 15-30% of cases with standard therapy; always verify eradication 3
Ignoring antibiotic resistance patterns: In areas with >15% clarithromycin resistance, empiric triple therapy has only 10-30% success rates—consider susceptibility testing 1, 7